about
KRAS oncogene in lung cancer: focus on molecularly driven clinical trials[De novo cancer after solid organ transplantation: Epidemiology, prognosis and management].Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.Alternative Neisseria spp. type IV pilin glycosylation with a glyceramido acetamido trideoxyhexose residue[Are cancer outpatients ready for e-medicine?]PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIsUnravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis.Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.[Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs].Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinomaTrastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.[Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017].What Do Older Adults Know About Their Cancer Diagnosis and Treatment? The ELCAPA-08 Cohort Study.Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.[Medical management of cholangiocarcinomas in 2015].Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy.Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives.Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction[Genealogy of lymph node and visceral metastases in colorectal cancer: "sisters" or "cousins"?]Guidelines and tumor boards are required for solid organ recipients with de novo carcinomaSorafenib exposure decreases over time in patients with hepatocellular carcinoma[Internet as a tool in oncology: critical analysis][Immunotherapies and targeted therapies in medical oncology][Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden]Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinomaIntra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinomaAngiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directionsAxitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinomaPrediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validationsCharacteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients[A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research]
P50
Q26765353-E7352397-8C61-4CAE-B6FC-683990CD7F70Q30235557-35B5A4B3-6637-4C27-BC15-2DF006BF8191Q30402722-25B6C577-D549-45CC-BFBC-41F6C8D0C24CQ33297467-1947D408-4B5D-4323-95FC-05A84EABF8A8Q33450085-2CC83C14-CD0B-4794-84D6-20FC2C3CAC64Q33648598-E108A9B3-DA1E-41A3-BA37-0A9033AD5FABQ36750660-D1EC7BC3-2DAC-419F-ADFD-4AF329052F88Q38655202-2C224ACC-231F-49E2-B1FE-F83F93B34FF4Q38754762-C1CC6105-18C5-4114-82A7-C6657B4F0F99Q38828156-8010B429-4C37-48D1-987D-34D9EAC91138Q38846856-68C9CEE0-458F-4721-BB05-F0C909E68F6CQ39002590-C72278E5-2666-4619-A6F9-7810A5442689Q39485531-1314F772-5169-494C-9D31-D221B89F6C17Q40102467-FACECE28-5408-4A4A-ABEC-DA2B952123DBQ42428002-8FB14475-10CD-42C2-9327-07EAC32CDCC2Q47100522-EF1F671C-619B-4E9C-9B19-CBC9048AB73DQ47400640-115E9F9B-EC6D-4997-954B-F3DF5174F0FEQ48274997-B049912D-7501-48E8-8402-F2E8FE350F27Q50518147-B6A9DA67-7BFF-4B95-A9F6-66A8AF186F9DQ50803386-3F807311-4BF0-4DA5-BBEA-AF51176FCE31Q51008413-9195830F-226B-41D2-BF3E-3AA1D652EF72Q53116694-C2CE37CA-9C51-4BD5-B987-D6FB94C6329CQ53162460-DB8A4009-6A99-4EE0-BFC3-E1119BBEE9F7Q53348236-508BAA41-5F0F-4879-9AAC-B0FC7A3EF95CQ54268558-EB21DEA4-0A18-4C18-874F-0F40DE1AA11FQ55191991-E5FBB983-59EA-4535-AA3F-BD2246640532Q58148566-F18A86FA-8724-4085-B998-84C5C567D72BQ59353813-807E29D8-9A09-42B4-AF6A-9077C800268AQ64100926-9E80FD04-0506-4C94-B787-E206FA7CB693Q82263349-B11A34BB-498D-4DC1-B12D-93BD97748893Q84595289-9EE59C8E-FB8A-4287-AEC3-71A6311702AFQ86943196-18CF3E93-499D-4BFD-8829-3A8E05D28018Q91027983-FAD7AF3D-468B-48E9-BA04-F39B6F71C855Q91193615-8421900A-1FF3-4FBC-A248-A302CB9FF7E5Q91433947-705C08E3-73BE-4E08-B9D3-06432A46C38FQ91553137-8727EBAF-DEAA-4004-8BBD-20C90757E6AEQ91926670-E47B461B-2398-49A5-AAA0-46B63233E168Q92076296-FC73A16E-B63F-436E-B11A-9BD58DA9C25BQ92451360-788FAD1F-CC35-43DA-850D-9474338A1903Q93107952-8140A1C3-7531-488D-84EF-4174DF1926C0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Benoit Rousseau
@ast
Benoit Rousseau
@en
Benoit Rousseau
@es
Benoit Rousseau
@nl
type
label
Benoit Rousseau
@ast
Benoit Rousseau
@en
Benoit Rousseau
@es
Benoit Rousseau
@nl
prefLabel
Benoit Rousseau
@ast
Benoit Rousseau
@en
Benoit Rousseau
@es
Benoit Rousseau
@nl
P106
P31
P496
0000-0003-3556-5178